Aims/hypothesis Previous studies have suggested that the haemoglobin glycation index (HGI) can be used as a predictor of diabetes-related complications in individuals with type 1 and type 2 diabetes. We investigated whether HGI was a predictor of adverse outcomes of intensive glucose lowering and of diabetes-related complications in general, using data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Methods We studied participants in the ADVANCE trial with data available for baseline HbA 1c and fasting plasma glucose (FPG) (n = 11,083). HGI is the difference between observed HbA 1c and HbA 1c predicted from a simple linear regression of HbA 1c on FPG. Using Cox regression, we investigated the association between HGI, both categorised and continuous, and adverse outcomes, considering treatment allocation (intensive or standard glucose control) and compared prediction of HGI and HbA 1c .
Introduction
HbA 1c is an established means of monitoring average blood glucose levels and a surrogate marker of the effect of glucoselowering interventions [1] . It is highly associated with the risk for diabetes-related complications, in particular those of microvascular origin [2] [3] [4] [5] . Although HbA 1c is almost universally accepted to guide and monitor diabetes treatment, its use in clinical practice has arguable limitations. There is a proposed inter-individual variation in the propensity for glycation, in both healthy individuals and those with diabetes [6] [7] [8] [9] [10] [11] [12] [13] , limiting the use of HbA 1c as a one-size-fits-all measurement. Moreover, the value of HbA 1c as a surrogate endpoint was questioned by the results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, where HbA 1c lowering may have had detrimental effects on the risk of premature mortality [14] . Therefore, 'the lower the better' may not universally hold for HbA 1c , and additional (bio)markers might be useful to individualise treatment targets and risk prediction [15] .
The haemoglobin glycation index (HGI) quantifies the variation in the relation between HbA 1c and the plasma glucose concentration [16] . For any individual within a study population, HGI is defined as the difference between the observed HbA 1c and the fitted value from a simple linear model that predicts HbA 1c from the fasting plasma glucose (FPG) concentration, i.e. the residual from the fitted linear regression line. In previous studies, HGI was normally distributed, stable over time and consistent over a wide range of blood glucose concentrations [17] [18] [19] [20] . In an analysis in individuals with type 1 diabetes in the DCCT, a high HGI was associated with the risk for and progression of retino-and nephropathy [21] . In an analysis of the ACCORD trial, only participants in the highest HGI third were at higher risk for mortality and those with high HGI showed no benefit on cardiovascular outcomes after intensive glucose lowering, in contrast to participants with a low or intermediate HGI [16] . The use of HGI is not without controversy, as in the DCCT population it was shown that the effect of HGI on microvascular complications disappeared after adjustment for the effect of HbA 1c [22] . However, the use of HbA 1c in type 1 diabetes is undisputed, whereas in individuals with type 2 diabetes, HbA 1c seems to have shortcomings, as demonstrated by the ACCORD trial.
The aim of this study was to assess whether HGI is a predictor of adverse outcomes of intensive glucose-lowering therapy and a predictor of diabetes-related complications in the cohort of individuals with type 2 diabetes recruited for the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial (ClinicalTrials.gov registration no. NCT00145925) [23] . Additionally, we aimed to compare the predictive values of HGI and HbA 1c to assess the possible added value of HGI beyond HbA 1c .
Methods

ADVANCE trial
In the ADVANCE trial, 11,140 individuals with type 2 diabetes and a history of, or a risk factor for, vascular disease were randomised in a factorial design between two BP-lowering strategies and two glucose-lowering strategies [24] . Glucoselowering treatment was either standard (based on local guidelines) or intensive, starting with gliclazide (30-120 mg daily, modified release) and adding other medication as necessary (based on the study protocol and discretion of the treating physician) to achieve a HbA 1c level of ≤48 mmol/mol (≤6.5%). Primary endpoints were a composite of major macro-and microvascular events. Study participants were, on average, 66 years old, with a mean diabetes duration of 8 years and a mean baseline HbA 1c of 59 mmol/mol (7.5%). After a follow-up of 5 years, mean HbA 1c was 48 mmol/mol (6.5%) in the intensively treated group vs 56 mmol/mol (7.3%) in the standard group. Intensive glucose-lowering treatment reduced the combination of macro-and microvascular events, mainly due to a 20% reduction in nephropathy, at the cost of an 86% increase in the risk of severe hypoglycaemia.
Present study
HGI We excluded 57 individuals with missing baseline HbA 1c (n = 54) or baseline FPG (n = 3). For the 11,083 remaining individuals, we fitted a linear regression. The Statistical analysis We compared baseline characteristics between the low, intermediate and high HGI groups using ANOVA or Kruskal-Wallis tests for continuous variables, depending on the distribution, and χ 2 tests for categorical variables. We used Cox proportional hazard regression models to analyse the association between baseline HGI and time to event for all four outcomes, with adjustment for covariates. We studied separately: (1) the treatment-modifying effect of HGI; and (2) the effect of HGI independent of treatment allocation-the first to make a comparison with the results from the ACCORD reanalysis, the latter as it seems more relevant for use in clinical practice where individuals will undergo variable treatment regimens. To assess whether HGI was better than time-matched (baseline) HbA 1c we added HbA 1c as a covariate to our models and used HbA 1c instead of HGI as predicting variable to compare the effect on outcomes.
Treatment-modifying effect of HGI We investigated the effect of intensive glucose control on outcomes across HGI groups, by adding the interaction term between HGI group and treatment allocation (intensive or standard glucose-lowering therapy) to the model with HGI and treatment. We adjusted the model for age, sex, ethnic origin (Asian or non-Asian), BMI, duration of type 2 diabetes, history of macro-and microvascular events, current drinking and smoking habits, use of glucoselowering medication, use of BP-lowering drugs, systolic and diastolic BP, haemoglobin, renal function (eGFR), LDL-, HDLand total cholesterol and triacylglycerol. We added baseline HbA 1c to the before-mentioned covariates in a separate analysis. Finally, we assessed the associations between HbA 1c (instead of HGI) as the exposure variable and outcomes, adjusted for the same covariates and studied the interaction between treatment and HbA 1c .
Effect of HGI independent of treatment allocation We assessed the association between HGI and outcomes, irrespective of treatment, for the low, intermediate and high HGI group, as well as for HGI as a continuous variable. The low HGI group served as the reference group in the comparison. We adjusted for the identical set of standard covariates (with and without HbA 1c ). Again, we assessed the associations between HbA 1c (instead of HGI) as the exposure variable and outcomes, adjusted for the same covariates.
As only 1.5% of data were missing, no imputation was carried out. Significance levels were set at a p < 0.05. Statistical analyses were performed using SAS Enterprise Guide 7.1 (SAS STAT 9.4; SAS Institute, Cary, NC, USA).
Results
In this population, HGI showed a normal distribution, ranging from −6.46 to 8.99, with a mean of 0 (SD 1.20). When dividing the study population into thirds, HGI cut-off points were ≤−0.53 for the low, −0.52 to 0.28 for the intermediate and ≥0.29 for the high HGI group. Mean baseline HGI was −1.14 (SD 0.57) in the low, −0.14 (SD 0.23) in the intermediate and 1.29 (SD 0.99) in the high HGI group (Table 1) .
There were some significant differences in baseline characteristics between the HGI groups ( Table 1) . Individuals in the high HGI group had the longest duration of diabetes and a higher proportion used glucose-lowering medication. More of those in the high HGI group were smokers, but fewer consumed alcohol. The prevalence of previous microvascular events was highest in the high HGI group. Almost half of the individuals in the high HGI group were of Asian origin, in contrast to a third in the low and intermediate group. HbA 1c levels increased from low to high HGI group and FPG was lowest in the intermediate HGI group. Table 2 shows the adjusted HRs based on HGI group and treatment allocation (intensive or standard glucose-lowering therapy). The effect of treatment allocation on macro-and microvascular complications was similar across the three HGI groups. However, the effect of intensive therapy on mortality risk differed between HGI groups (p for interaction = 0.011). In the high HGI group the mortality risk was significantly lower with intensive therapy (adjusted HR 0.74 [95% CI 0.61, 0.91]; p = 0.003), whereas intensive treatment did not diminish risk for mortality in the low and intermediate groups. This effect remained after additional adjustment for baseline HbA 1c level (electronic supplementary material (ESM) Table 1 ). With regard to severe hypoglycaemia, absolute rates increased progressively as HGI rose, regardless of whether individuals received intensive or standard treatment. The effect of intensive treatment on the risk for severe hypoglycaemia was not different between HGI thirds, as indicated by the non-significant p value for interaction (0.228). To compare the predictive value of HGI with HbA 1c , we assessed the interaction between treatment and HbA 1c groups using the same multivariable model (ESM Table 2 ). Here, there was no difference in effect of intensive treatment on mortality risk across the three HbA 1c groups (p for interaction = 0.530). Individuals with intermediate and high HbA 1c were at greater risk for severe hypoglycaemia when intensively treated, contrary to individuals with low HGI.
Treatment-modifying effect of HGI
Effect of HGI independent of treatment allocation Table 3 ). Again, we assessed the association between HbA 1c groups and adverse outcomes using the same multivariable model (ESM Table 4 ). Likewise, the high HbA 1c group had a higher risk for macro-and microvascular complications and mortality compared with the low HbA 1c group. HRs exceeded those seen for HGI. HbA 1c was not associated with the risk of severe hypoglycaemia.
When we considered HGI as a continuous variable, every 1 SD (=1.20 HGI) increase resulted in a 14% risk increase for microvascular complications, a 17% risk increase for macrovascular complications and a 16% risk increase for mortality (p < 0.0001) (Fig. 2) 
Discussion
With this analysis of the ADVANCE trial we showed that HGI predicts diabetes-related complications, but no better than HbA 1c. Irrespective of treatment allocation, the high HGI group (i.e. individuals with higher HbA 1c levels than would be expected for their given fasting glucose levels) was at higher risk for macro-and microvascular complications and mortality compared with the low HGI group. Every SD increase in HGI gave a significant 14-17% risk increase for these three outcomes. Hypothetically, this could be explained by a higher propensity for glycation of membrane proteins and lipids other than haemoglobin, with these glycation products leading to microvascular complications and atherogenesis. This effect disappeared after additional adjustment for HbA 1c , which is in line with results on the effect of HGI in individuals with type 1 diabetes in the DCCT [22] . However, this might be considered over-adjustment, as HGI is so strongly related to HbA 1c (HGI is HbA 1c corrected for FPG). In our study, intensive treatment carried a lower risk for mortality in individuals with a high HGI, whereas it had no effect on mortality in individuals with a low or intermediate HGI. Thus, a high HGI identified a group of people who benefitted most from intensive HbA 1c -lowering treatment in terms of mortality. This finding remained after additional correction for baseline HbA 1c , but was not replicated by using HbA 1c as the predicting variable, as we found no interaction between treatment and HbA 1c groups. Overall, the estimates for the effect of intensive treatment as shown in Table 2 remained unchanged after additional adjustment for HbA 1c (ESM Table 1 ), which is not surprising given that HGI is just a linear function of HbA 1c and FPG (i.e. it is HbA 1c -(a + b × FPG), where a and b are regression coefficients). The above directly opposes the results of an analysis of the ACCORD trial, where intensive treatment was associated with a significantly higher, instead of lower, risk for mortality in participants with a high HGI [16] . Thus, the hypothesis put forward that a high HGI results in more complications due to more intensive treatment to lower HbA 1c than is necessary to lower plasma glucose is not supported by our study.
The inconsistency between the effect of HGI on outcomes in these two large outcome studies might be explained by important differences between ACCORD and ADVANCE. First, glucose-treatment strategies were different, although both took HbA 1c as predominant measure of glycaemia and both took glucose into account. Glycaemic treatment in ACCORD was intensified when HbA 1 c level was e Model was adjusted for age, sex, ethnic origin (Asian vs non-Asian), BMI, duration of type 2 diabetes, history of macro-and microvascular events, current drinking and smoking, use of glucose-lowering drugs, use of BP-lowering drugs, systolic BP, diastolic BP, haemoglobin, renal function (eGFR), LDL-, HDL-and total cholesterol, triacylglycerol f p value for interaction between treatment effect and HGI group ≥42 mmol/mol (≥6%) or when >50% of the self-monitored pre-or 2 h post-meal capillary glucose values were above a certain threshold [26] .The treatment algorithm of the ADVANCE trial took discrepancies between HbA 1c levels and blood glucose values into account simultaneously [23] . When HbA 1c level was >47 mmol/mol (>6.5%) but fasting glucose was relatively low, mealtime interventions were optimised and the reliability of the tests was checked. Also ACCORD had participants who started with a higher HbA 1c and had a lower target HbA 1c in the intensive group. Further, 30% more individuals under intensive treatment received insulin in ACCORD compared with ADVANCE [5] . This is in agreement with the observation that FPG was treated more aggressively in ACCORD, with a decrease of 3.3 mmol/l from baseline to end of trial, compared with 1.9 mmol/l in ADVANCE. Moreover, in ADVANCE all participants received a sulfonylurea derivative at the start, while in ACCORD thiazolidinedione treatment was frequently used. The additional treatments differed between studies (i.e. use of aspirin and statins was substantially higher in ACCORD).
Second, ACCORD was terminated prematurely, limiting the follow-up, and potentially misrepresenting estimates (no adjustment to standard errors was made for early stopping). Third, ADVANCE and ACCORD were discordant in the major findings, including mortality. In ACCORD, mortality rates were significantly higher in the intervention arm compared with the control arm [14] , whereas in ADVANCE there were no significant differences in mortality between arms [23] . Post hoc, it was shown that intensively treated ACCORD participants with a high average on-treatment HbA 1c (>53 mmol/ mol [>7%]) were at greater risk for mortality than intensively treated participants with average HbA 1c <53 mmol/mol (<7%) or standard-treated individuals with average HbA 1c >53 mmol/mol (>7%) [27] . The number of individuals experiencing severe hypoglycaemia was significantly higher with intensive treatment in both studies, but the event rates per person-year were higher in the ACCORD trial (3.5% per year with intensive treatment vs 1.0% per year in the control arm), whereas in ADVANCE rates were 0.7% per year in intensive treatment vs 0.4% per year in the control arm. We found no Table 3 Cox proportional hazard regression analysis for major macrovascular events, major microvascular events, total mortality and severe hypoglycaemia predicted by HGI group (using the low group as a reference) [28] . Baseline characteristics of individuals with high HGI accorded with previous studies [16, 29] . The ethnic differences (i.e. more Asians in the high HGI group) are consistent with the observation that ethnicity influences the haemoglobin glycation, with, in general, relative higher HbA 1c levels in non-whites [17, [30] [31] [32] [33] . However, regression equations in Asian (HbA 1c = 4.6 + 0.373 × FPG, r 2 = 0.41) and non-Asian (HbA 1c = 4.5 + 0.340 × FPG, r 2 = 0.40) participants were very similar. The combination of a slightly younger age, longer duration of diabetes (on average 2 years), more use of glucoselowering medication and higher rates of microvascular complications suggests that individuals with high HGI might have a form of diabetes that is more difficult to treat. This in itself can be the cause of diabetes-related complications, but there is also potential for confounding, as these characteristics could well be explained by the higher HbA 1c levels in individuals with high HGI [22] . The HGI concept is based on the proposed interindividual variation in haemoglobin glycation, while an adequate method for measuring glycation rate is lacking. Erythrocyte lifespan is a major determinant of the variation in haemoglobin glycation and subtle natural variation in senescence of erythrocytes is complex to quantify [34, 35] . To our knowledge, there are no studies focusing on the pathophysiological mechanism explaining both the biological variation in haemoglobin glycation as well as the reason for the possible increased risk for complications associated with higher glycation rates. This study was limited by a single FPG measurement to determine the relationship with HbA 1c , so we could not take diurnal changes in plasma glucose into account. A measure of average glucose would have been preferred, but was not available in our data and might not be in clinical practice where individuals often use oral glucose-lowering medication only. The DCCT used seven-point glucose profiles to assess HGI [21] , while ACCORD used FPG only [16] .
In conclusion, we found that HGI predicted macro-and microvascular complications and mortality, but was no better than HbA 1c , which was a stronger predictor for these outcomes. Moreover, HbA 1c is simpler than HGI. High HGI does predict risk for mortality with intensive treatment, but results are the opposite of those from ACCORD. Bringing all this together, the evidence does not support the clinical relevance and usefulness of HGI above HbA 1c .
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